Dimerization Drug Ap20187
Dimerization Drug Ap20187 - Related Videos
10:39
Visualization of ATP Synthase Dimers in Mitochondria by Electron Cryo-tomography
0 Views •
Cited by 43 •
2014
We present a protocol of how to collect and process electron cryo-tomograms of whole mitochondria. The technique provides detailed insights into the structure, function, and organization of large membrane protein complexes in native biological membranes.
10:44
Isolating Free Carbenes, their Mixed Dimers and Organic Radicals
0 Views •
Cited by 5 •
2019
We present protocols for the isolation of stable heterocyclic carbenes. The synthesis of a cyclic (alkyl)(amino) carbene (CAAC) and an N-heterocyclic carbene (NHC) is demonstrated using filter cannulas and Schlenk technique. We furthermore present the synthesis of the related oxygen-sensitive, electron-rich mixed “Wanzlick dimer” and the reduced stable organic radical.
08:52
Chemical Dimerization-Induced Protein Condensates on Telomeres
0 Views •
Cited by 10 •
2021
This protocol illustrates a chemically induced protein dimerization system to create condensates on chromatin. The formation of promyelocytic leukemia (PML) nuclear body on telomeres with chemical dimerizers is demonstrated. Droplet growth, dissolution, localization and composition are monitored with live cell imaging, immunofluorescence (IF) and fluorescence in situ hybridization (FISH).
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
0 Views •
Cited by 4 •
2016
Here we describe a protocol using the web-based drug repurposing hypothesis generation tool: "RE:fine Drugs." This protocol can be modified to a user's preferences at the level of the query type (gene, drug or disease) and/or the range of available advanced options.
08:57
Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization
0 Views •
Cited by 1 •
2019
A native Western blot method for analyzing endogenous interferon regulatory factor 5 dimerization in the CAL-1 plasmacytoid dendritic cell line is described. This protocol can be applied to other cell lines as well.
FAQs
Modified FKBP domains serve as the ligand-recognition elements on engineered fusion proteins. When AP20187 binds these domains, it increases the proximity of the attached protein partners rather than acting as a general, untargeted cellular stimulus. This design lets investigators connect a defined molecular interaction to the behavior of the particular fusion construct.
The result depends on what functional module is attached to the FKBP-containing fusion proteins. Induced proximity may activate a signaling module, promote protease assembly, or change protein localization. Thus, AP20187 does not impose one universal response; the engineered architecture determines which biochemical event follows dimerization and which cellular outcome can be measured.
Because the interaction is ligand-controlled and reversible, researchers can examine cellular behavior under defined AP20187-dependent conditions rather than relying only on constitutive activity. This control helps distinguish effects associated with induced protein proximity from baseline behavior of the engineered construct, making the approach useful for controlled biochemical experiments.
A typical workflow begins by establishing cells or a biochemical system containing the engineered FKBP fusion proteins, followed by exposure to AP20187 so the partners are brought together. Researchers then assess the construct-specific consequence, such as signaling activation, protease assembly, altered localization, or another measurable cellular response.
Inducible caspase platforms are useful when researchers need to test a conditional apoptosis system. AP20187 brings the engineered caspase components into proximity, allowing the construct to be evaluated as a ligand-dependent switch for a cellular outcome. This application connects controlled protein assembly with studies of engineered cell behavior and measurable cell responses.
Within biochemistry, the reagent helps connect molecular interaction control with downstream cellular readouts. By placing modified FKBP domains on selected fusion partners, investigators can test whether bringing those partners together changes signaling, protease behavior, localization, or engineered cell activity. This makes the system useful for dissecting cause-and-effect relationships in designed protein networks.